SELLAS Life Sciences logo

SELLAS Life Sciences

SLS | NASDAQ
Chart Builder DCF Calculator
$7.47
-$0.39 (-4.96%)
At close: Nov 16, 2026, 4:00 PM ET
$7.99
+$0.52 (+6.96%)
After-hours: Nov 16, 2026, 7:59 PM ET
-4.96%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
33.7
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #693/1021 (Top 68%)

Key Statistics

Market Data

Market Cap $1.52B
1D Range
7.24 8.34
52W Range
1.39 15.46

Valuation (TTM)

PE -37.35
PB 11.55
EV/EBITDA -38.83

Valuation (NTM)

Forward PE N/A
Forward PEG 1.87
Price Target $35.00
Loading financial charts...

Profile

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's l...

Sector Healthcare
Industry Biotechnology
Employees 13
IPO Date Mar 12, 2008
Fiscal Year January - December

Latest News

Sellas Life Sciences Stock Jumps on Trial Results Timeline

3 days ago · schaeffersresearch.com

Sellas Life Sciences Stock Jumps on Trial Results Timeline
SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update

4 days ago · globenewswire.com

SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026

13 days ago · globenewswire.com

SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026
SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer

2 months ago · globenewswire.com

SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer
SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer

3 months ago · globenewswire.com

SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer
When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges

3 months ago · benzinga.com

When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges
SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

3 months ago · globenewswire.com

SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
SELLAS Life Sciences: Strong Buy-Imminent Catalyst, Dual-Platform Pipeline, And A Market That Hasn't Caught Up

4 months ago · seekingalpha.com

SELLAS Life Sciences: Strong Buy-Imminent Catalyst, Dual-Platform Pipeline, And A Market That Hasn't Caught Up
SELLAS Life Sciences Shares Slip Wednesday as Price Tests $16 Resistance Wall

4 months ago · benzinga.com

SELLAS Life Sciences Shares Slip Wednesday as Price Tests $16 Resistance Wall
SELLAS Life Sciences Shares Fall Tuesday: What's Driving The Move?

5 months ago · benzinga.com

SELLAS Life Sciences Shares Fall Tuesday: What's Driving The Move?

Earnings

Next Earnings
Mar 25, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
1
Consensus
Buy
Price Target
$35.00
Upside
+368.54%
Buy (1)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.